| Syk tyrosine kinase is downregulated by methylation and functions as a tumor suppressor in malignant melanoma. | skin, |
| Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma. | oral |
| Syk has a role in limiting proliferation and invasion of epithelial cells during normal morphogenesis, and is a tumor suppressor for breast cancer | breast, |
| Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. | pancreatic, |
| Nuclear Syk possesses biological activities associated with tumor suppression in mammary epithelial cells. | None |
| Hypermethylation leads to lose of the syk gene expression in human breast carcinoma and may be correlated to oncogenesis, metastasis of breast carcinoma. | breast, |
| Methylation of Syk promoter is correlated to oncogenesis and metastasis of gastric carcinoma. | gastric, |
| Data suggest that Syk is a protooncogene involved in the transformation of lymphocytes, thus making Syk a potential target for the treatment of leukemia. | leukemia, |
| Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. | lung, |
| Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. | None |
| The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. | None |
| T-cell-specific human ITK-Syk oncogene in mice leads to early polyclonal T cell lymphoproliferation with B cell expansion. It induces terminal T cell differentiation via Blimp-1, eliminating oncogene-expressing cells early in development. | None |
| Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk. | None |